- Home
- EQS vs DARE Comparison
EQS vs DARE Comparison
Compare EQS & DARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EQS
- DARE
- Stock Information
- Founded
- EQS 1991
- DARE 2015
- Country
- EQS United States
- DARE United States
- Employees
- EQS N/A
- DARE N/A
- Industry
- EQS Finance Companies
- DARE Biotechnology: Pharmaceutical Preparations
- Sector
- EQS Finance
- DARE Health Care
- Exchange
- EQS Nasdaq
- DARE Nasdaq
- Market Cap
- EQS 30.7M
- DARE 28.0M
- IPO Year
- EQS N/A
- DARE N/A
- Fundamental
- Price
- EQS $2.26
- DARE $2.15
- Analyst Decision
- EQS
- DARE Strong Buy
- Analyst Count
- EQS 0
- DARE 2
- Target Price
- EQS N/A
- DARE $10.00
- AVG Volume (30 Days)
- EQS 92.8K
- DARE 182.2K
- Earning Date
- EQS 01-01-0001
- DARE 08-14-2025
- Dividend Yield
- EQS N/A
- DARE N/A
- EPS Growth
- EQS N/A
- DARE N/A
- EPS
- EQS N/A
- DARE N/A
- Revenue
- EQS $1,355,000.00
- DARE N/A
- Revenue This Year
- EQS N/A
- DARE $74,787.57
- Revenue Next Year
- EQS N/A
- DARE $141.76
- P/E Ratio
- EQS N/A
- DARE N/A
- Revenue Growth
- EQS 60.35
- DARE N/A
- 52 Week Low
- EQS $0.74
- DARE $1.83
- 52 Week High
- EQS $2.44
- DARE $9.19
- Technical
- Relative Strength Index (RSI)
- EQS 77.80
- DARE 48.66
- Support Level
- EQS $2.19
- DARE $2.00
- Resistance Level
- EQS $2.44
- DARE $2.19
- Average True Range (ATR)
- EQS 0.11
- DARE 0.09
- MACD
- EQS 0.02
- DARE 0.03
- Stochastic Oscillator
- EQS 70.97
- DARE 51.72
About EQS Equus Total Return Inc.
Equus Total Return Inc is a United States-based closed-end management investment company. It invests mainly in companies pursuing growth either through acquisition or organically, leveraged buyouts, management buyouts, and recapitalizations of existing businesses or special situations, and achieves capital appreciation by making investments in equity and equity-oriented securities issued by privately-owned companies or smaller public companies in transactions.
About DARE Dare Bioscience Inc.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.